Adding dulaglutide or semaglutide to metformin significantly improved HbA1c, fasting glucose, and BMI over 12 months in overweight type 2 diabetes patients compared to metformin alone.
12-month benefitGLP-1 agonist + metformin showed sustained improvements in HbA1c, fasting glucose, and BMI over a full year
What the researchers found
GLP-1 receptor agonists combined with metformin produced statistically significant improvements in HbA1c, fasting glucose, and BMI at 6 and 12 months compared to metformin alone, with comparable safety profiles.
Why it matters
Most type 2 diabetes patients begin treatment with metformin alone. This real-world evidence supports adding GLP-1 drugs earlier in treatment for overweight patients, showing meaningful improvements in both blood sugar and weight that persist over a year.
The numbers in context
Outcomes measured at baseline, 3 months, and 6 months. Significant improvements in HbA1c, fasting glucose, and BMI with combination therapy.
How the study worked
Real-world cohort study comparing metformin alone (n=35) versus metformin plus dulaglutide or semaglutide (n=32) in overweight/obese type 2 diabetes patients from July 2021 to June 2022, using repeated measures ANOVA.
Who was studied
Overweight T2DM patients on metformin (July 2021-June 2022)
What this study cannot tell us
Small sample size (67 total). Non-randomized real-world design. Dulaglutide and semaglutide were grouped together rather than compared separately. Metformin dosing may have varied. Single-center study limits generalizability.
How to read the evidence
Moderate evidence — real-world cohort study with small sample size and non-randomized design, though it confirms findings from larger clinical trials.
When this study was published
Published in 2024 with data from 2021-2022, reflecting current GLP-1 agonist prescribing practices.
The bigger picture
As GLP-1 receptor agonists become more widely available, real-world evidence like this helps clinicians understand how these drugs perform outside the controlled setting of clinical trials. The dual benefit of blood sugar and weight management addresses two of the most critical concerns in overweight type 2 diabetes patients.
Questions still open
- Would dulaglutide and semaglutide show different efficacy profiles if compared head-to-head in this population?
- Do the benefits persist beyond 12 months, and do they translate to reduced cardiovascular events?
- At what BMI threshold does adding a GLP-1 agonist to metformin become most cost-effective?
Common questions
Is it better to take a GLP-1 drug with metformin or switch from metformin?
Were there more side effects when combining GLP-1 drugs with metformin?
Read the original research
Real world study of GLP-1 receptor agonists in overweight or obese type 2 diabetes by using repeated measurement analysis of variance.
Medicine, 103(32), e38879
Citation
Yang, Wanying; Zhou, Xiangming; Miao, Yuanyuan; Wang, Lu; Zhao, Yunhui; Ke, Tingyu; Ban, Lili. (2024). Real world study of GLP-1 receptor agonists in overweight or obese type 2 diabetes by using repeated measurement analysis of variance.. Medicine, 103(32), e38879. https://doi.org/10.1097/MD.0000000000038879